Hsbc Global Res Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by Hsbc Global Res to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

REGN has been the topic of several other reports. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $798.00 price objective on the stock. Citigroup increased their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $757.91.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $787.32 on Monday. The stock has a market capitalization of $82.75 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $800.99. The company’s 50-day simple moving average is $623.31 and its 200-day simple moving average is $579.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $12.46 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $27,000. Finally, Colonial Trust Advisors acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.